Vetter starts construction on new Saarlouis production site

By AI, Created 5:02 PM UTC, May 18, 2026, /AGP/ – Vetter has begun building a new pharmaceutical production site in Saarlouis, Germany, with commercial injectable-drug manufacturing planned for 2031. The company says the project will expand capacity, create up to 2,000 jobs over time, and strengthen its manufacturing footprint in Europe and the U.S.

Why it matters: - Vetter is adding major production capacity for injectable drugs at a time of growing demand for complex drug manufacturing. - The Saarlouis project is expected to bring 400 to 500 jobs initially, with the potential to reach 2,000 jobs at full buildout. - The site adds to Vetter’s investment push in Germany, Austria and the U.S., which the company is using to deepen its global manufacturing footprint.

What happened: - Vetter held a groundbreaking ceremony on May 13, 2026, to mark the start of construction on a new site in Saarlouis, Saarland, Germany. - The first construction phase covers a 50,000-square-meter manufacturing site on a 95-acre industrial property. - The planned commissioning date for the site is 2031. - The project is set to support commercial production of injectable drugs. - State and regional representatives joined Vetter and project partners at the ceremony.

The details: - Vetter plans to invest almost half a billion euros in the site by the time the project is commissioned. - The first expansion phase includes production-related facilities such as laboratories and warehouses. - Three cleanrooms are planned at the outset. - Two cleanrooms will be used to fill pre-sterilized syringes. - One cleanroom will be used to fill vials. - The facility is designed for aseptic production of innovative and complex drug products. - Senator h.c. Udo J. Vetter, chairman of the advisory board and a member of the owner family, said the new location is meant to support sustainable growth and expand capacity in complex drug product manufacturing. - Anke Rehlinger, Saarland’s minister president, said the project creates new opportunities for the region and its people. - Jürgen Barke, Saarland’s minister of economic affairs, innovation, digitalization and energy, said the investment strengthens the region’s position in the pharmaceutical industry.

Between the lines: - The Saarlouis buildout signals that Vetter is betting on long-term demand for advanced injectable-drug production rather than short-term output gains. - The job creation estimates suggest the project could become a major industrial anchor for Saarland if the buildout proceeds as planned. - The public endorsements from state leaders show the project is also being framed as a regional economic-development win, not just a corporate expansion.

What’s next: - Vetter will move through the first construction phase ahead of planned commissioning in 2031. - The company expects the site to ramp from initial job creation to a much larger workforce as the first phase advances. - Vetter’s broader investment program in Europe and the U.S. remains part of its capacity-expansion strategy. - More information is available on Vetter’s LinkedIn post.